LifeTime and improving European healthcare through cell-based interceptive medicine
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Rajewsky, Nicolaus
- dc.contributor.author Bertero, Michela G.
- dc.contributor.author Martí Renom, Marc A.
- dc.contributor.author LifeTime Community
- dc.date.accessioned 2020-11-10T07:05:51Z
- dc.date.available 2020-11-10T07:05:51Z
- dc.date.issued 2020
- dc.description.abstract LifeTime aims to track, understand and target human cells during the onset and progression of complex diseases and their response to therapy at single-cell resolution. This mission will be implemented through the development and integration of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during progression from health to disease. Analysis of such large molecular and clinical datasets will discover molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. Timely detection and interception of disease embedded in an ethical and patient-centered vision will be achieved through interactions across academia, hospitals, patient-associations, health data management systems and industry. Applying this strategy to key medical challenges in cancer, neurological, infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade.
- dc.description.sponsorship We would like to acknowledge all participants that have attended and contributed to LifeTime meetings and workshops through many exciting presentations and discussions. We thank Johannes Richers for artwork. LifeTime has received funding from the European Unionʼs Horizon 2020 research and innovation framework programme under Grant agreement 820431.
- dc.format.mimetype application/pdf
- dc.identifier.citation Rajewsky N, Almouzni G, Gorski SA, Aerts S, Amit I, Bertero MG et al. LifeTime and improving European healthcare through cell-based interceptive medicine. Nature. 2020 Sep 7; 587:377-86. DOI: 10.1038/s41586-020-2715-9
- dc.identifier.doi http://dx.doi.org/10.1038/s41586-020-2715-9
- dc.identifier.issn 0028-0836
- dc.identifier.uri http://hdl.handle.net/10230/45696
- dc.language.iso eng
- dc.publisher Nature Research
- dc.relation.ispartof Nature. 2020 Sep 7; 587:377-86
- dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/820431
- dc.rights © The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Biomarkers
- dc.subject.keyword Diseases
- dc.subject.keyword Systems biology
- dc.title LifeTime and improving European healthcare through cell-based interceptive medicine
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion